Latest news with #Age-RelatedMacularDegeneration
Yahoo
7 days ago
- Business
- Yahoo
Historic $40 Million Gift to CU Anschutz Dept. of Ophthalmology will Fuel Research and New Therapies
The anonymous gift to Colorado's only academic eye center will boost research into treating and curing the most serious eye diseases while investing in new technology and recruiting top talent AURORA, Colo., June 3, 2025 /PRNewswire/ -- The University of Colorado Anschutz Medical Campus announced today that its Department of Ophthalmology received a historic $40 million gift to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on basic science and harness artificial intelligence to revolutionize vision care in the years ahead. "This transformational gift was made possible by one of our longstanding philanthropic partners, whose family holds a deep passion for improving health and healthcare in Colorado and beyond," said CU Anschutz Chancellor Donald M. Elliman. "Their generous investment has established the Department of Ophthalmology Research Endowment, which will provide resources to speed innovation and research with the potential to save and restore sight." Part of the gift is available for immediate use, including funding for critical basic science research in vision preservation and restoration, while the rest will provide ongoing support well into the future. The donor, a patient at the Sue Anschutz-Rodgers Eye Center, has chosen to remain anonymous, yet their gift will accelerate the ophthalmology program that is already an innovative, national leader in the quest to treat and cure eye disease. "We have a tremendous opportunity to fuel our research enterprise which is fundamental to clinical care," said Naresh Mandava, MD, chair of the CU Department of Ophthalmology and the Sue Anschutz-Rodgers Endowed Chair in Retinal Diseases. "This gift will allow us to translate technology from the lab to the patient faster than before." The timing couldn't be better. Some 10,000 Americans turn 65 each day and that comes with an increase in diseases like glaucoma and macular degeneration. "We have the chance to change the fate of those with these diseases with funding like this," Mandava said. The Sue Anschutz-Rodgers Eye Center is the sole academic eye center in Colorado and serves about 115,000 patients a year. It has already launched a range of initiatives aimed at eradicating persistent eye diseases. They include: The CellSight program involves teams of investigators from across disciplines working to develop novel stem cell-based therapies to save and restore eyesight in blinding diseases. The University of Colorado Age-Related Macular Degeneration (AMD) registry allows researchers to investigate AMD, which is projected to affect almost 300 million people worldwide by 2040. Nearly 2,000 patients from the Sue Anschutz-Rodgers Eye Center are enrolled. Artificial intelligence is being used to build algorithms to help diagnose macular degeneration and glaucoma and screen for blinding diseases in infants. "We are taking big datasets and seeing if we can identify the mechanisms that cause disease," Mandava said. "We can also identify which patients will benefit from new drug therapies. So that opens the door for pharmaceutical companies to study their drugs on new patient populations earlier in the course of disease." The CU Anschutz Department of Ophthalmology is a national leader in innovation. It has won 60 patents since 2020. At least 13 technologies have been invented here and licensed to industry like the world renowned Kahook Dual Blade, designed for minimally invasive glaucoma surgery. It was invented by Malik Kahook, MD, Slater Family Endowed Chair in Ophthalmology and professor at the CU School of Medicine. These innovations have spurred millions in investments, with several companies spun out of the department. "The donor and their family have been longtime patients of the Eye Center. This generous gift reflects their deep appreciation for the exceptional care they've received and their desire for others to benefit from the same high-quality eye care at CU for generations to come," said John H. Sampson, MD, PhD, MBA, Dean of the University of Colorado School of Medicine. Mandava said he and his colleagues are honored that someone had enough confidence in the eye center to bestow such a large gift. It confirms just how precious sight is to people and the importance of vision science research programs. "There is a tremendous responsibility that comes with this," he said. "We have to deliver on every level to meet the full potential of this gift. And more importantly, we have to honor the intent of this investment which is to bring sight to patients." About the University of Colorado Anschutz Medical CampusThe University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado – which see more than two million adult and pediatric patient visits yearly. Innovative, interconnected and highly collaborative, the CU Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by $910 million in annual research funding, including $757 million in sponsored awards and $153 million in philanthropic gifts for research. Find the latest University of Colorado Anschutz Medical Campus news here. Contact: David Kelly, University of Colorado Anschutz Medical Campus, View original content to download multimedia: SOURCE University of Colorado Anschutz Medical Campus Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Health
- Yahoo
Age-Related Macular Degeneration (AMD) Market Forecast Report and Company Analysis 2025-2033 Featuring Hoffmann - La Roche, Bayer, Abbvie, GSK, Novartis, Regeneron Pharma, Bausch, Alimera Science
The aging population, rising rates of lifestyle-related risk factors, improved diagnostic tools, more awareness, and the creation of novel AMD treatments and therapies are the main factors propelling the Age-Related Macular Degeneration (AMD) market. Age-Related Macular Degeneration (AMD) Market Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration (AMD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Macular Degeneration (AMD) Market is expected to reach US$ 20.88 billion by 2033 from US$ 11.42 billion in 2024, with a CAGR of 6.94% from 2025 to 2033 In affluent societies, age-related macular degeneration (AMD) is the primary cause of blindness in older adults. It is an age-related eye condition that gradually impairs the central vision required for reading, driving, facial recognition, and color vision. As AMD worsens, central vision is lost, impairing quality of life by preventing many patients from reading, writing, or recognizing color and detail. Recent advancements in genetic technologies have led to the discovery of several variants that have been demonstrated to have distinct relationships with AMD, despite the fact that the precise functional pathophysiology of AMD is still macula, the core portion of the retina, gradually degenerates in age-related macular degeneration, resulting in central vision loss. Based on its clinical characteristics, such as drusen, aberrant pigmentation, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV), age-related macular degeneration can be categorized as early, intermediate, or late. Another way to describe age-related macular degeneration is as wet (exudative or neovascular) or dry (atrophic or non-neovascular).The market is expected to be primarily driven by the introduction of new products, a robust product pipeline, and an increase in the prevalence of AMD. According to the Population Reference Bureau, the number of Americans 65 and older is expected to increase by 47%, from 58 million in 2022 to 82 million in 2050. Today, the U.S. population is older than it has ever of the main elements driving category expansion is the aging population. About 200,000 new cases of wet AMD are discovered in North America each year, according to Genentech. Wet AMD causes 90 percent of legal blindness but only accounts for about 10 percent of events. Because of the unchecked proliferation of new blood vessels in the eye, which results in fluid leaking into the macula, this advanced variety can cause rapid and severe vision Drivers for the Age-Related Macular Degeneration (AMD) Market Innovative Treatment OptionsThe management of age-related macular degeneration (AMD) has changed dramatically as a result of the introduction of novel medications, including as anti-VEGF (vascular endothelial growth factor) therapy. These therapies have been shown to stabilize or enhance vision in a large number of patients by preventing aberrant blood vessel formation in the retina, which is a defining feature of wet AMD. Furthermore, by focusing on the genetic defects that cause AMD, advances in gene therapy hold the promise of treating the disease's underlying causes. The market is expanding as a result of these new treatment options, which can delay the course of AMD and enhance patients' quality of life. It is anticipated that more ground-breaking treatments will surface as research progresses, increasing the range of available treatments and improving patient AwarenessGrowing public knowledge of age-related macular degeneration (AMD) is a major factor in the market's growth. The public is being educated about the symptoms, risk factors, and significance of early diagnosis through awareness programs run by patient advocacy organizations, healthcare organizations, and ophthalmology experts. People are more inclined to seek early screening as they become more knowledgeable about the illness, which can result in earlier therapies that can improve outcomes. More people are identifying AMD in its early stages thanks to better access to healthcare, especially in poorer nations. The market for AMD is developing as a result of increased awareness and proactive healthcare strategies, which are driving up demand for diagnostic and treatment Healthcare InvestmentsNew and better treatments for Age-Related Macular Degeneration (AMD) are being developed more quickly thanks to increased funding for ophthalmology and retinal research. More research into improved diagnostic methods, cutting-edge treatments, and even cures for AMD is being made possible by increased funding from the public and commercial sectors. Additionally, this investment is supporting clinical trials for potential medications and therapies that could provide better treatments for both wet and dry forms of AMD. The market for AMD is seeing the introduction of innovative treatments and diagnostic tools due to technological breakthroughs and an increasing emphasis on retinal health. These developments will ultimately improve patient care and propel market in the Age-Related Macular Degeneration (AMD) Market High Treatment CostsPatients may need repeated injections over long periods of time, and treatments for Age-Related Macular Degeneration (AMD), particularly anti-VEGF medications, can be costly. Both patients and healthcare systems may experience severe financial hardship as a result of these exorbitant expenses, especially in areas with low and moderate incomes where access to cutting-edge treatments may be of Early DiagnosisIn its early stages, patients may not detect any signs of age-related macular degeneration (AMD), which frequently develops slowly. Because of this, many people wait until they have experienced severe vision loss before seeking medical help. Early detection can be difficult due to the disease's sluggish progression, and by the time patients receive a diagnosis, the illness is frequently well advanced. Company Analysis: Overview, Key Persons, Recent Development & Strategies, Financial Insights Hoffmann - La Roche Ltd. Bayer AG Abbvie GSK Plc Novartis AG Regeneron Pharmaceuticals Bausch Health Companies Inc. Alimera Sciences Inc. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $11.42 Billion Forecasted Market Value (USD) by 2033 $20.88 Billion Compound Annual Growth Rate 6.9% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Age-Related Macular Degeneration Market6. Market Share6.1 Disease Type6.2 Product6.3 Distribution Channel6.4 Country7. Disease Type7.1 Dry Age-Related Macular Degeneration Market7.2 Wet Age-Related Macular Degeneration Market8. Product8.1 Eylea8.2 Lucentis8.3 Beovu8.4 Others9. Distribution Channel9.1 Hospital Pharmacy9.2 Specialty Pharma9.3 Online Pharmacy10. Country10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 UAE11. Porter's Five Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Age-Related Macular Degeneration (AMD) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Globe and Mail
12-02-2025
- Business
- Globe and Mail
AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR
"Regeneron Pharmaceuticals Inc. is a biotechnology company that focuses on the development, manufacturing, and distribution of therapeutic drugs such as Eylea and Eylea HD (high dose) in the US for the treatment of various retinal disorders including wet Age-Related Macular Degeneration (wAMD)." Key players in the Age-Related Macular Degeneration (AMD) drugs market include Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland) The global Age-related Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust CAGR of 10.7%. This growth is driven by rising AMD prevalence linked to lifestyle changes, increased R&D investment leading to more drug approvals, and improved reimbursement policies. The market is particularly expanding in developing countries and is witnessing a shift towards innovative therapies like gene therapy. However, challenges like high treatment costs and the off-label use of drugs such as Avastin hinder market potential. Notably, Eylea remains the leading product, while dry AMD therapies are expected to grow rapidly due to escalating cases among the aging population. North America is projected to be the fastest-growing region, with significant annual AMD case increases. Key players include Regeneron, Bayer, and Novartis, among others, with recent developments indicating a strong focus on new therapeutic solutions. Download PDF Brochure: Browse in-depth TOC on " Age-related Macular Degeneration (AMD) Drugs Market" 378 - Tables 54 - Figures 336 - Pages Based on molecules, the global Age-Related Macular Degeneration (AMD) drugs market has been segmented into Ranibizumab, Aflibercept, Faricimab, Pegcetacoplan, and other molecules including conbercept, brolucizumab, avacincaptad pegol, and bevacizumab-gamma among others. In 2023, aflibercept held the largest share of the Age-Related Macular Degeneration (AMD) drugs market by molecule. This large share of the molecule can be attributed to the high adoption of this molecule for the treatment of the wet or neovascular form of AMD. This adoption is due to the high affinity of the molecule for VEGF proteins preventing activation of native VEGF receptors and reducing angiogenesis and vascular permeability. Moreover, the efficacy of the molecule is supported by various research studies comparing the effectiveness of this molecule to other molecules used for AMD treatment. Additionally, the ongoing development of novel drug delivery methods and biosimilars for this molecule further supports the growth of the market of this molecule. Based on the type of AMD, the global Age-Related Macular Degeneration (AMD) drugs market has been segmented into wet AMD and dry AMD. In 2023, the wet AMD disease segment accounted for the largest share of the AMD market by type of AMD. The large share of wet AMD can be attributed to the rising prevalence of this disease affecting more than 20 million individuals globally. Reports from leading pharmaceutical companies highlight that more than 200,000 cases of wet AMD are reported in the US every year. This increase in wet AMD cases is attributed to the rising geriatric population with the World Health Organization (WHO) estimating a 2x increase in the number of individuals over 60 years of age by 2050. This market is also supported by new entrants targeting patients earlier in the disease cascade, with new drugs such as new entrants targeting patients earlier in the disease cascade with new drugs such as OPT-302 and KSI-301 being developed for the treatment of this disease. Based on end users, the global age-related macular degeneration (AMD) drugs market has been segmented into hospitals, specialty centers, and long-term care facilities. Hospitals accounted for the largest share of the AMD drugs market by end user in 2023. The large share of this segment is attributed to the rising prevalence of AMD cases and the ability of hospitals to provide advanced healthcare infrastructure and specialized treatment capabilities that aid in the treatment of patients with AMD. Furthermore, hospitals also support research that facilitates the development of better treatment for various diseases including AMD. Hospitals collaborate with pharmaceutical companies to ensure the optimal availability of AMD drugs for patients while providing comprehensive care, including diagnostics, treatment administration, and patient monitoring to enhance treatment outcome for the patients. The key regional markets for age-related macular degeneration (AMD) drugs market are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2023, North America accounted for the largest share of the market. This can be attributed to the increasing AMD cases in the region with reports from major pharmaceutical companies highlighting the occurrence of more than 200,000 new cases of AMD every year in the US. A rise in obesity, smoking, and poor diet in this region further contributes to the increase in the number of AMD cases. Additionally, an increase in the number of approvals for AMD drugs in the region further supports the market growth. Advanced healthcare infrastructure in these regions, including access to specialists and diagnostic tools, supports early detection and treatment. Request Sample Pages: The prominent players in the global Age-Related Macular Degeneration (AMD) market are Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals (US), Coherus BioSciences (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG (Germany), Formycon AG (Germany), Biocon. (India), Outlook Therapeutics, Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Chengdu Kanghong Biotech Company (China) and Sandoz Group AG (Switzerland). The market also includes players, such as Stealth BioTherapeutics Inc. (US), Ocular Therapeutix, Inc. (US), Opthea Limited (Australia), Kodiak Sciences Inc. (US), Innovent (China), Bio-Thera Solution (China), Alvotech (Iceland), Alteogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), Amgen Inc. (US), Ocumension Therapeutics. (China), and Adverum Biotechnologies, Inc. (US), that have drug candidates in phase 3 clinical trials. Regeneron Pharmaceuticals Inc. (US): Regeneron Pharmaceuticals Inc. is a biotechnology company that focuses on the development, manufacturing, and distribution of therapeutic drugs such as Eylea and Eylea HD (high dose) in the US for the treatment of various retinal disorders including wet Age-Related Macular Degeneration (wAMD). Eylea is one of the most adopted therapeutic drugs for the treatment of wet AMD across the globe. The company has partnered with major pharmaceutical companies such as Bayer AG to manufacture and distribute the drugs outside the US. Regeneron has operations in over 12 countries across the Asia Pacific, Europe, and North America, and conducts clinical trials in more than 60 countries. In 2023, the company allocated USD 96.2 million to improve Eylea HD, a higher hose of its already successful AMD drug Eylea. This drug allows patients to obtain similar therapeutic results with less number of injections reducing the treatment burden on the patients. The company has also developed innovative technologies like TRAPS and VelociSuite, which are used for the development of bispecific antibodies, essential for the development of next-generation ophthalmic drugs. F. Hoffmann-La Roche Ltd (Switzerland): Roche is a major pharmaceutical company that offers three FDA-approved drugs for the treatment of wet AMD among other retinal diseases: Lucentis, Vabysmo, and Susvimo, the company also provides Avastin (Bevacizumab) which is widely used as an off-label drug for the treatment of wet AMD owing to its affordability. In 2023, the company invested approximately 22% (USD 14.7 billion) of its annual revenue in R&D for the development of new drugs and exploring advanced research methods, including computational biology. The company has received marketing approvals for its AMD drugs in many countries, with recent expansions into markets like India. Roche's Genentech Ophthalmology Co-pay Program helps cover drug and administration costs making treatments more affordable. The company has operations in over 95 countries and offers a wide range of therapeutic products for a variety of diseases and disorders. Novartis AG (Switzerland): Novartis AG is a biotechnology company that focuses on the development and distribution of innovative medicines across key therapeutic areas, including cardiovascular, renal, metabolic, immunology, neuroscience, ophthalmology, and oncology. In 2023, Novartis became a pure-play innovative medicines company by spinning off its Sandoz generic and biosimilar business unit. The company strongly focuses on ophthalmology, and markets FDA-approved drugs like Lucentis and Beovu (brolucizumab) for treating wet Age-Related Macular Degeneration (AMD) across the globe. Novartis is also conducting phase 3 clinical trials for Beovu to expand its use for diabetic retinopathy, highlighting the company's focus on innovation and expanding treatment options. The company operates in over 130 countries and uses contract structures such as pay-over-time and outcome-based agreements to make its products more affordable and accessible to patients. For more information, Inquire Now!
